Zacks.com on MSN
Can Alnylam's Pipeline Drugs Sustain Long-Term Growth Ahead?
Alnylam Pharmaceuticals ALNY currently markets four approved drugs — Onpattro, Givlaari, Oxlumo and Amvuttra — that together generated $2.99 billion in net product revenues, representing a 81% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results